Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients
CONCLUSIONS: Overall, these results suggest that the analysis of lymphocyte subsets along with plasma cell immunophenotyping could be a potential index for determining the prognosis of MM patients.PMID:38377849 | DOI:10.1016/j.intimp.2024.111640 (Source: International Immunopharmacology)
Source: International Immunopharmacology - February 20, 2024 Category: Allergy & Immunology Authors: Zhaoyun Liu Hongli Shen Mei Han Xianghong Zhao Hui Liu Kai Ding Jia Song Rong Fu Source Type: research
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
Clin Pharmacol Ther. 2024 Feb 20. doi: 10.1002/cpt.3189. Online ahead of print.ABSTRACTThe US Food and Drug Administration can require risk evaluation and mitigation strategy (REMS) programs for prescription drugs to ensure the benefits of use outweigh the risks. We conducted a national survey of physicians' experiences prescribing eight REMS-covered drugs: (1) ambrisentan; (2) bosentan; (3) clozapine; (4) isotretinoin; (5-7) the multiple myeloma (MM) drugs lenalidomide, pomalidomide, thalidomide; and (8) sodium oxybate. Between May 2022 and January 2023, we surveyed 5,331 physician prescribers of these drugs, and 1,295 (2...
Source: Clinical Pharmacology and Therapeutics - February 20, 2024 Category: Drugs & Pharmacology Authors: Ameet Sarpatwari Zhigang Lu Massimiliano Russo Heidi Zakoul Su Been Lee Gita A Toyserkani Esther H Zhou Cynthia LaCivita Katherine Hyatt Hawkins Shaw Laura Zendel Gerald J Dal Pan Aaron S Kesselheim Source Type: research
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | DOI:10.1177/15330338241232554 (Source: Cell Research)
Source: Cell Research - February 16, 2024 Category: Cytology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | DOI:10.1177/15330338241232554 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - February 16, 2024 Category: Cancer & Oncology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | DOI:10.1177/15330338241232554 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - February 16, 2024 Category: Cancer & Oncology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | PMC:PMC10874153 | DOI:10.1177/15330338241232554 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - February 16, 2024 Category: Cancer & Oncology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | PMC:PMC10874153 | DOI:10.1177/15330338241232554 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - February 16, 2024 Category: Cancer & Oncology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Acquired von Willebrand syndrome associated with a smoldering multiple myeloma, successfully treated by daratumumab, lenalidomide and dexamethasone
CONCLUSION: Daratumumab, lenalidomide, and dexamethasone demonstrated as a rapid and effective treatment for a patient with severe AvWS and multiple bleeding complications.PMID:38359808 | DOI:10.1159/000536650 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Michael Iarossi Marie-Christiane Madeleine Vekemans Nicolas Weynants Cedric Hermans Source Type: research
Lenalidomide treatment of isolated central nervous system relapse in acute lymphoblastic leukemia after HSCT and CAR-T cell therapy
CONCLUSION: Lenalidomide might be a therapeutic strategy for isolated CNS relapse after HSCT and CAR-T cell therapy.PMID:38359803 | DOI:10.1159/000537719 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Qing Zhang Yi Dong Zhimin Zhai Lili Tao Qianshan Tao Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
